摘要目的 探讨同时测定乳腺癌原发灶与腋淋巴结转移灶分子分型的临床治疗中的价值. 方法 选取2011年1月至2016年1月徐州医科大学附属宿迁医院乳腺外科收治的428例单侧乳腺癌伴腋窝淋巴结转移的女性患者. 采用免疫组化法检测患者的雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(Her-2)、Ki67在原发灶与腋窝淋巴结转移灶中的表达. 结果 428例乳腺癌患者中,31例患者存在原发灶与腋窝淋巴结转移灶分子分型不一致,其中14例原发灶Lu-minal A型,10例原发灶 Luminal B 型,4例原发灶 HER-2过表达,3例原发灶三阴性乳腺癌.结论 部分乳腺癌患者的分子分型在原发灶与同期腋窝淋巴结转移灶中存在不一致,对于乳腺癌伴有腋窝淋巴结转移的患者常规行原发灶与腋窝淋巴结转移灶免疫组化检测,根据原发灶与腋窝淋巴结转移灶分子分型制定个体化治疗方案,使患者获得较好的治疗效果.

abstractsObjective To investigate the value of molecular typing in primary tumor and axillary lymph node metastasis of breast cancer.Methods A total of 428 cases of female patients with unilateral breast cancer with axillary lymph node metastasis were selected from January 2011 to January 2016.ER, PR,Her-2 and Ki67 were detected by immunohistochemistry in primary tumor and axillary lymph node me-tastasis.Results Molecular typing of primary tumor and axillary lymph node metastases was inconsistent in 31 patients (31/428),luminal A of primary tumors in 14 cases,luminal B of primary tumors in 10 cases, while 4 cases of Her-2 over-expression and 3 cases of triple negative breast cancer in axillary lymph node metastases.Conclusion There was an inconsistency in primary tumor and axillary lymph node metastasis of some breast cancer.Immunohistochemistry for primary tumor and axillary lymph node metastasis of breast cancer associated with axillary lymph node metastasis should routinely carried out.Based on molecular typ-ing of primary tumor and axillary lymph node metastasis to develop individualized treatment programs,pa-tients could benefit from it.